98 related articles for article (PubMed ID: 1601678)
21. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
[TBL] [Abstract][Full Text] [Related]
22. Use of transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum-containing drugs.
Yardley MP; Davies CM; Stevens JC
Br J Audiol; 1998 Oct; 32(5):305-16. PubMed ID: 9845029
[TBL] [Abstract][Full Text] [Related]
23. Correlation of transiently evoked otoacoustic emission measures to auditory thresholds.
Balatsouras D; Kaberos A; Karapantzos E; Homsioglou E; Economou NC; Korres S
Med Sci Monit; 2004 Feb; 10(2):MT24-30. PubMed ID: 14737052
[TBL] [Abstract][Full Text] [Related]
24. Changes in transient-evoked otoacoustic emission levels with negative tympanometric peak pressure in infants and toddlers.
Prieve BA; Calandruccio L; Fitzgerald T; Mazevski A; Georgantas LM
Ear Hear; 2008 Aug; 29(4):533-42. PubMed ID: 18469719
[TBL] [Abstract][Full Text] [Related]
25. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
Delehaye E; Capobianco S; Bertetto IB; Meloni F
Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
[TBL] [Abstract][Full Text] [Related]
26. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
27. [Monitoring hearing during ototoxic cisplatin therapy].
Kluba J; Kluba U; von Specht H; Mittler U
Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
[TBL] [Abstract][Full Text] [Related]
28. Perilymphatic application of alpha-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin.
Wolters FL; Klis SF; Hamers FP; de Groot JC; Smoorenburg GF
Hear Res; 2004 Mar; 189(1-2):31-40. PubMed ID: 14987750
[TBL] [Abstract][Full Text] [Related]
29. Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer.
Yilmaz S; Oktem F; Karaman E
Eur Arch Otorhinolaryngol; 2010 Jul; 267(7):1041-4. PubMed ID: 19946777
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology.
Böheim K; Bichler E
Arch Otorhinolaryngol; 1985; 242(1):1-6. PubMed ID: 4041173
[TBL] [Abstract][Full Text] [Related]
31. Tone burst-evoked otoacoustic emissions in cats with acoustic overstimulation and anoxia.
Iwasaki S; Mizuta K; Hoshino T
Hear Res; 1998 Apr; 118(1-2):83-9. PubMed ID: 9606063
[TBL] [Abstract][Full Text] [Related]
32. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions.
Ozturan O; Jerger J; Lew H; Lynch GR
Auris Nasus Larynx; 1996; 23():147-51. PubMed ID: 8809338
[TBL] [Abstract][Full Text] [Related]
34. Modification of spontaneous and evoked otoacoustic emissions and associated psychoacoustic microstructure by aspirin consumption.
Long GR; Tubis A
J Acoust Soc Am; 1988 Oct; 84(4):1343-53. PubMed ID: 3198870
[TBL] [Abstract][Full Text] [Related]
35. Light microscopy study of cisplatin-induced ototoxicity in rats.
de Freitas MR; de Castro Brito GA; de Carvalho JV; Gomes RM; Barreto Martins MJ; de Albuquerque Ribeiro R
J Laryngol Otol; 2009 Jun; 123(6):590-7. PubMed ID: 19144244
[TBL] [Abstract][Full Text] [Related]
36. TEOAE monitoring of Cisplatin induced ototoxicity in guinea pigs: the protective effect of vitamin B treatment.
Güneri EA; Serbetçioğlu B; Ikiz AO; Güneri A; Ceryan K
Auris Nasus Larynx; 2001 Jan; 28(1):9-14. PubMed ID: 11137357
[TBL] [Abstract][Full Text] [Related]
37. [Cisplatin ototoxicity: the experience of the Institute of Oncology in Bari].
Grammatica L; Achille G; Cortese M; Casaula M; Mininni F
Acta Otorhinolaryngol Ital; 1992; 12(4):383-8. PubMed ID: 1301675
[TBL] [Abstract][Full Text] [Related]
38. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.
Jalali MM; Saedi HS; Saadat F
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2783-2789. PubMed ID: 34213608
[TBL] [Abstract][Full Text] [Related]
39. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
Eiamprapai P; Yamamoto N; Hiraumi H; Ogino-Nishimura E; Kitamura M; Hirano S; Ito J
Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
[TBL] [Abstract][Full Text] [Related]
40. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
